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j ourna l homepage: www.eb iomed ic ine.comEditorialEngineering Viruses to Fight CancerWith EMA approval in December 2015, and US FDA approval in
October 2015 of an oncolytic herpesvirus for the treatment of non-
resectable melanoma, we now have a novel class of anticancer agents to
add to our ever-promising arsenal of cancer (immuno-) therapeutics.
Talimogen laherparapvec (T-VEC) therapy involves direct,
intratumoral injection of a herpes simplex type 1 (HSV-1) virus which
has been genetically altered to decrease pathogenicity, and to stimulate
the host's own immune response by both expressing the immune-
stimulatory cytokine GM-CSF as well as increasing the presentation of
tumor antigens by the infected cell. In this sense, the approach is “two-
pronged” in that the virus is not only designed to infect and destroy
cancer cells and leave healthy ones alone, but—in doing so—the virus
infection and subsequent breakdown of the tumor cells help to stimulate
the immune system to recognize and kill these infected cells, as well as
other cells expressing the same patient-speciﬁc tumor antigens.
A Phase 3 randomized clinical trial (OPTiM) published earlier in
2015 looked at T-VEC treatment in stage IIIB-IV melanoma patients.
Results indicated that T-VEC was relatively well tolerated, and signiﬁ-
cantly improved the overall durable response rate (DRR) patients com-
pared to GM-CSF treatment alone (16.3% versus 2.1%, respectively),
meeting the primary endpoint of the study. DRR to T-VEC was even
more pronounced in patients with less advanced melanoma (33%,
compared to 0% in the GM-CSF treatment group). Although overall sur-
vival was not signiﬁcantly extended (4.4 months, P= .051), the results
arewidely heralded as amajor success as they provide proof of principle
that oncolytic viruses are a viable class of anticancer treatments ready
for application in the clinic.
Indeed, several other clinical trials are underway to examine
whether other cancers may be similarly treated with either modiﬁed
HSV or other engineered viruses. Researchers at Duke University, for
example, have shown encouraging results in a Phase 1 study treating
recurrent glioblastoma patients with modiﬁed poliovirus, also by
injecting the therapeutic virus directly into the patient's tumor. This
particular poliovirus strain was altered in the laboratory (20 years
ago) by replacing part of its RNA (the internal ribosomal entry site, or
IRES) with the equivalent IRES sequence from human rhinovirus. The
resultant chimeric virus is still able to bind to and enter glioblastoma
cells, which happen to express high amounts of poliovirus receptor —
but the genetic alteration reduces its neuropathogenic potential.
Although results from the trial using this virus are still quite preliminary,
they are indeed striking—with a number of patients apparently
experiencing a complete disappearance of their tumors. Given that
this type of cancer often has a very poor prognosis, this is an encouraging
potential new option for the ﬁeld.http://dx.doi.org/10.1016/j.ebiom.2016.01.014
2352-3964/© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NCAnother promising example of oncolytic viruses as a treatment
option is the use of an altered vaccinia virus, JX-594 (pexastimogene
devacirepvec [Pexa-Vec]), for the treatment of hepatocellular carcinoma
(HCC). Following positive Phase 2 results wheremedian survival was sig-
niﬁcantly extended, a global Phase 3 randomized clinical trial has just
begun recruiting (PHOCUS) which uses JX-594 in combination with the
kinase inhibitor sorafenib for the treatment of advanced HCC patients.
Control patients will receive sorafenib alone, which is already in clinical
use as the only approvedHCCpharmacological therapeutic. The backbone
of JX-594 is a strain that has been used safely formany years for smallpox
vaccination. In addition, the virus has a genetic deletion which removes
the viral thymidine kinase (TK) gene. This alteration renders the virus
dependent upon cellular TK,which is expressed at persistently high levels
in cancer cells—therefore providing a replication advantage in cancer cells
over healthy ones. Like T-VEC, JX-594 also expresses the immune-
stimulatory GM-CSF protein to help boost host anti-tumor responses.
A search performed in January 2016 for clinical trials (www.
clinicaltrials.gov) employing the use of oncolytic viruses as a therapeu-
tic returned dozens of trials, at all stages of investigation. These trials
employ the use of multiple viral vectors and target a wide range
of cancers including ovarian cancer, metastatic colorectal cancer,
advanced pancreatic adenocarcinoma and a variety of other solid
tumors. Given the recent approval of T-VEC as the ﬁrst oncolytic virus
approved for the clinic, this list is expected to increase as we think of
new ways to use this exciting new tool to combat cancer.
But what's next for the ﬁeld?
A better mechanistic understanding of how these therapies arework-
ing (when they work well), and what fails when they don't work, will
help researchers design next-generation oncolytic virus therapies. For
example, what factors render a cancer cell more or less susceptible to in-
fection and lysis by the virus?Which viral vectors are best suited for each
particular cancer, and for speciﬁc modes of delivery?What host immune
pathways are necessary to mount an effective response to the infected/
lysed tumor cells, and how can this be increased at both the injected
tumor site as well as systemically at peripheral tumors? What immuno-
suppressive pathways are working against effective oncolysis?
Related to this last point, a clinical trial is already underway looking
at T-VEC in combination with the CTLA-4 inhibitor ipilimumab in late-
stage melanoma patients. Given the huge promise of checkpoint inhib-
itors and these early encouraging results with ﬁrst-generation oncolytic
virus therapies, we eagerly await the next chapter of this exciting new
cancer treatment modality.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
